Articles
Cancer survivorship can mean different things to different survivors. The consequences of cancer and its treatments can affect individuals in many ways.
Cancer patients with pain or depression often also have physical symptoms, such as fatigue, dry mouth and nausea, that can cause disability, a new study shows.
“This study strengthens the case for improving the recognition and treatment of somatic symptoms in patients with cancer,” the researchers said in a news release.
Many patients with advanced cancers and a poor prognosis receive routine screenings—mammograms, Pap smears, prostate-specific antigen (PSA) tests—for other cancers even though there is little likelihood of these tests to provide benefit, according to a new study released in the October issue of JAMA.
Patients with advanced non–small-cell lung cancer (NSCLC) achieved a significant increase in overall survival when tumor treating fields (TTF) therapy was added to pemetrexed every 3 weeks, according to data released by Novocure at the European Society for Medical Oncology Congress.
Women with ductal carcinoma in situ (DCIS) who have mammographically dense breasts may be at increased risk for subsequent breast cancer, especially in the contralateral breast, researchers at Kaiser Permanente report.
A study of men with a family history of breast cancer revealed that nearly 80% were unaware of their own risk for breast cancer, and all of them said that their healthcare provider had not discussed the disease with them.
Preliminary results of an ongoing trial suggest that a combination of trastuzumab, bevacizumab, and docetaxel is safe and effective as first-line therapy in women with metastatic breast cancer (MBC).
Fourteen of the 18 patients treated to date had a partial response or stable disease, a clinical benefit rate of 77.7, the investigators report.
Adding the monoclonal antibody rituximab to chemotherapy signicantly increases both progression-free and overall survival in previously untreated patients with chronic lymphocytic leukemia (CLL), the German Lymphocytic Leukaemia Study Group reports.
The recently approved taxane cabazitaxel significantly improved overall survival in men with castration-resistant prostate cancer in a multinational phase 3 study.
The TROPIC investigators found that men treated with cabazitaxel plus prednisone had 30% lower risk of death compared with patients treated with mitoxantrone plus prednisone.
Results of a trial by the Children's Oncology Group indicate that children with intermediate-risk neuroblastoma can be successfully treated with a shorter duration and lower doses of chemotherapy than are currently used.